| Treating breast cancer in the 21st century: emerging biological therapies G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero Journal of Cancer 4 (2), 117, 2013 | 191 | 2013 |
| A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer AJ Montero, K Avancha, S Glück, G Lopes Breast cancer research and treatment 132 (2), 747-751, 2012 | 66 | 2012 |
| A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer G Lopes, S Glück, K Avancha, AJ Montero Breast cancer research and treatment 137 (1), 187-193, 2013 | 29 | 2013 |
| Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer V Diaby, G Adunlin, SB Zeichner, K Avancha, G Lopes, S Gluck, ... Breast cancer research and treatment 147 (2), 433-441, 2014 | 20 | 2014 |
| O. 03: cost effectiveness of immune checkpoint inhibitors in non-small cell lung cancer relative to PD-L1 expression P Aguiar, R De Mello, H Tadokoro, I Santoro, H Babiker, K Avancha, ... Journal of Thoracic Oncology 11 (10), S169-S170, 2016 | 7 | 2016 |
| Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013; 4 (2): 117-32 G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero | 5 | |
| Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel. A Chopra, S Gluck, AJ Montero, KKVR Avancha, G Lopes Journal of Clinical Oncology 30 (15_suppl), e15107-e15107, 2012 | 4 | 2012 |
| Personalized management of breast cancer TL Holloway, I Jatoi Future Medicine Ltd., 2014 | 3 | 2014 |
| Cost-effectiveness of everolimus plus exemestane in post-menopausal hormone receptor positive metastatic breast cancer. SB Zeichner, KKVR Avancha, G Lopes, S Gluck, AJ Montero Journal of Clinical Oncology 31 (15_suppl), 6548-6548, 2013 | 3 | 2013 |
| Cost-effectiveness analysis of eribulin (E) versus treatment of physician’s choice (TPC) in patients (pts) with pretreated metastatic breast cancer (MBC). AJ Montero, KKVR Avancha, S Gluck, GL Lopes Journal of Clinical Oncology 30 (15_suppl), e16525-e16525, 2012 | 3 | 2012 |
| COST-EFFECTIVENESS ANALYSIS OF METASTATIC BREAST CANCER TREATMENTS: A STUDY BASED ON THE BOLERO-2 TRIAL V Diaby The 36th Annual Meeting of the Society for Medical Decision Making, 2014 | | 2014 |
| EGF receptor inhibitors: Patient selection and clinical outcomes S Warsch, G Tinoco, S Glück, K Avancha, AJ Montero Personalized Management of Breast Cancer, 69-78, 2014 | | 2014 |
| Design and synthesis of core structural intermediates for novel HIV-1 protease inhibitors & synthesis, biological activity and molecular modeling of novel 20S proteasome inhibitors KKVR Avancha | | 2006 |
| POSTER SECTION C VP MIMETICS Bioorg. Med. Chem 13, 501, 2005 | | 2005 |
| Travis L Holloway I Jatoi | | |
Alberto J. MonteroUniversity Hospitals/Seidman Cancer Center Case Western Reserve UniversityVerified email at UHhospitals.org
